|ID||Components||Size (480 tests)|
|PK601-213||Human HER-2||10 μg|
|PK602-213||Biotinylated anti-HER-2 antibody||10 μg|
|PK604-213||Anti-HER-2 antibody||30 μg|
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development.
HER-2 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Herceptin®. Many investigational anti-HER-2 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
The enclosed ELISA assay kit for anti-HER-2 h-mAb in monkey serum is based on an enzyme immunoassay (ELISA) between recombinant HER-2 protein (ECD) and a biotinylated anti-HER-2 monoclonal antibody. The method employs the principle of competitive ELISA, allowing quantification of monoclonal anti-HER-2 antibodies in monkey serum.
The assay only involves the following steps:
1. Coat the plate with human HER-2;
2. Add the mixture of your sample and biotinylated anti-HER-2 antibody;
3. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate;
4. Record the OD readings and analyze the serum concentration.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
There is no requirement for the species and subtype of the antibody.
There is no longer a need to generate anti-drug antibodies for PK studies.
The use of the biotinylated antibody in the competitive ELISA significantly alleviates the issue of background noise issue that often occurs in traditional ELISA method.
Upon receipt, please store all items at -20℃.
After reconstitution, the stock solution should be kept at -80℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 6 months in lyophilized state;
-80℃ for 4 months under sterile conditions after reconstitution.
Inhibition of HER-2: biotinylated anti-HER-2 antibody binding by an anti-HER-2 antibody.
Serial dilutions of the Therapeutic Anti-HER-2 Antibody (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL) was added into HER-2: Biotinylated Anti-HER-2 Antibody binding reactions.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.